Description: NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Home Page: www.nextcure.com
9000 Virginia Manor Road
Beltsville,
MD
20705
United States
Phone:
240 399 4900
Officers
| Name | Title |
|---|---|
| Mr. Michael S. Richman MSBA | Co-Founder, CEO, President & Director |
| Dr. Solomon Langermann Ph.D. | Chief Scientific Officer |
| Dr. Lieping Chen M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board |
| Mr. Steven P. Cobourn CPA | Chief Financial Officer |
| Dr. Timothy Mayer Ph.D. | Chief Operating Officer |
| Mr. Kevin G. Shaw | Senior VP & General Counsel |
| Mr. Sourav Kundu Ph.D. | Senior Vice President of Development & Manufacturing |
| Dr. Sebastien Maloveste Ph.D. | Senior Vice President of Business Development |
| Dr. Udayan Guha M.D., Ph.D. | Senior Vice President of Clinical & Translational Development |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3985 |
| Price-to-Sales TTM: | 9.667 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 82 |